^
    2years
    A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions (clinicaltrials.gov)
    P1, N=35, Recruiting, Applied Pharmaceutical Science, Inc.
    New P1 trial • Metastases
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    APS03118
    almost3years
    The preclinical selectivity and activity of APS03118, a highly selective and potent next-generation RET inhibitor (AACR 2022)
    Selective RET inhibitors selpercatinib and pralsetinib were recently approved by the FDA and EMA for patients with RET-dependent NSCLC and thyroid cancers. APS03118 is a novel highly selective next-generation RET inhibitor that possesses potent in vitro and in vivo activity against a diverse range of RET alterations, including SFMs-mediated resistance. A first-in-human phase 1 trial for patients with RET-driven solid tumors with activating RET alterations is planned for 2022.
    Preclinical
    |
    RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B) • KDR (Kinase insert domain receptor) • CCDC6 (Coiled-Coil Domain Containing 6)
    |
    RET fusion • RET mutation • RET M918T • RET C634W • RET V804L • RET V804M • RET C634* • RET V804*
    |
    Retevmo (selpercatinib) • Gavreto (pralsetinib) • APS03118